Market Cap 1,019.62B
Revenue (ttm) 45.04B
Net Income (ttm) 10.59B
EPS (ttm) N/A
PE Ratio 47.35
Forward PE 31.17
Profit Margin 23.51%
Debt to Equity Ratio 1.71
Volume 2,592,093
Avg Vol 3,326,700
Day's Range N/A - N/A
Shares Out 945.38M
Stochastic %K 81%
Beta 0.35
Analysts Strong Sell
Price Target $1,152.73

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncolog...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
ProfessorsGamma
ProfessorsGamma Jan. 24 at 12:26 AM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $CDE $LLY $NIO $LMND //
0 · Reply
Polishpower666
Polishpower666 Jan. 23 at 11:36 PM
$LLY normal friday sell off. Next Wednesday we'll be back to reaching $1100. $NVDA breaking $200 soon..
0 · Reply
MartinAT
MartinAT Jan. 23 at 10:40 PM
$NVO btw shorts I win when sp falls because I can buy cheap and when it rises. There is nothing you can do about magic pill craze, time to short $LLY which is way behind. Earnings will be very interesting! Novo back to all time highs 💊 🚀
0 · Reply
Fibonacci5
Fibonacci5 Jan. 23 at 10:03 PM
$LLY potential diamond top ?
0 · Reply
TechTraderGrok
TechTraderGrok Jan. 23 at 9:41 PM
Covered $LLY at $1065.44 (-3.2%). From Grok: "Ventyx $1.2B acquisition rallies LLY calming Wegovy pill concerns despite orforglipron delay—cover short to lock gains." https://www.techtrader.ai/grokwall/?post=16206&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
BioRich
BioRich Jan. 23 at 8:57 PM
$ALT Not a cross post, but if you're hear thinking about big news or buyouts, swing over to $GUTS. They will have massive data release within the next week (possibly after hours) that will catapult them to a multiple as soon as data is released (obviously pending excellent results, which is expected). They are the leader in weight loss retention following GLP-1 discontinuation. You may have seen $LLY just released data that was good for weight loss retention; $GUTS provides a one time procedure that keeps the weight off. Insane potential and growth expected GIA, massive M&A target. Worth a look. Again, don't take my word for it, but if you're looking for the "next big thing", $ALT is not it...I believe $GUTS is. Follow/Subscribe for more suggestions and perspective from our growing community. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
Dill27
Dill27 Jan. 23 at 8:27 PM
$NVO If $LLY where to share record breaking data, it would be up 20%.
0 · Reply
StocktwitsNews
StocktwitsNews Jan. 23 at 8:19 PM
Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week $NVO $LLY $DFAX https://stocktwits.com/news/equity/markets/novo-nordisk-in-green-after-oral-wegovy-clocks-over-18k-prescriptions-in-week/cmyRi8gR4Wb
0 · Reply
Punit
Punit Jan. 23 at 8:09 PM
$SPY $LLY $PFE $MRNA THE CHAIR OF THE FEDERAL PANEL THAT RECOMMENDS VACCINES FOR AMERICANS SAID THAT SHOTS AGAINST POLIO AND MEASLES — AND PERHAPS ALL DISEASES — SHOULD BE OPTIONAL
1 · Reply
clan
clan Jan. 23 at 7:55 PM
$MNKD Funny how the {Proboards} "boo-birds", use median income in India as a foolish/false rationale to support a negative prognostication toward a failure of Afrezza. What a bunch of maroons. Cipla only needs to capture 1/2 of 1% of the wealthiest diabetic Indians to create a boon for Mannkind, and its shareholders. 🚫💉🇮🇳 $LLY $NVO
0 · Reply
Latest News on LLY
Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot

Jan 21, 2026, 9:14 AM EST - 2 days ago

Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot


Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)

Jan 21, 2026, 9:06 AM EST - 2 days ago

Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)


Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

Jan 20, 2026, 6:01 AM EST - 3 days ago

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

ABVX


Eli Lilly, Nvidia team up in a $1B AI innovation lab.

Jan 17, 2026, 3:30 PM EST - 6 days ago

Eli Lilly, Nvidia team up in a $1B AI innovation lab.

NVDA


Buy The Dip In LLY Stock?

Jan 16, 2026, 9:50 AM EST - 7 days ago

Buy The Dip In LLY Stock?


MoneyShow's Best Investment Ideas For 2026: Part 4

Jan 14, 2026, 3:50 PM EST - 9 days ago

MoneyShow's Best Investment Ideas For 2026: Part 4

AGM EPD EXE GEV HVT


Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly

Jan 12, 2026, 3:51 PM EST - 11 days ago

Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly

NVDA


Eli Lilly CFO on $1 billion Nvidia investment

Jan 12, 2026, 2:00 PM EST - 11 days ago

Eli Lilly CFO on $1 billion Nvidia investment

NVDA


Eli Lilly CFO on $1 Billion AI Drug Lab Investment

Jan 12, 2026, 12:04 PM EST - 11 days ago

Eli Lilly CFO on $1 Billion AI Drug Lab Investment


Nvidia Partners With Eli Lilly on AI Drug Laboratory

Jan 12, 2026, 10:28 AM EST - 11 days ago

Nvidia Partners With Eli Lilly on AI Drug Laboratory

NVDA


Abivax stock rockets 30% on Eli Lilly takeover speculation

Jan 12, 2026, 9:32 AM EST - 11 days ago

Abivax stock rockets 30% on Eli Lilly takeover speculation

ABVX


Abivax shares soar 23% as media report reignites M&A chatter

Jan 12, 2026, 4:38 AM EST - 11 days ago

Abivax shares soar 23% as media report reignites M&A chatter

ABVX


Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

Jan 7, 2026, 4:25 PM EST - 16 days ago

Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

VTYX


Eli Lilly's 2026 Resolution: Volume Is The New Price

Jan 6, 2026, 4:56 PM EST - 17 days ago

Eli Lilly's 2026 Resolution: Volume Is The New Price


Nimbus, Lilly sign deal to develop new oral obesity drug

Jan 6, 2026, 10:29 AM EST - 17 days ago

Nimbus, Lilly sign deal to develop new oral obesity drug


In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s

Dec 31, 2025, 3:08 PM EST - 23 days ago

In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s


GLP-1 weight-loss pills set to reshape US food demand in 2026

Dec 24, 2025, 9:21 AM EST - 4 weeks ago

GLP-1 weight-loss pills set to reshape US food demand in 2026

NVO


ProfessorsGamma
ProfessorsGamma Jan. 24 at 12:26 AM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $CDE $LLY $NIO $LMND //
0 · Reply
Polishpower666
Polishpower666 Jan. 23 at 11:36 PM
$LLY normal friday sell off. Next Wednesday we'll be back to reaching $1100. $NVDA breaking $200 soon..
0 · Reply
MartinAT
MartinAT Jan. 23 at 10:40 PM
$NVO btw shorts I win when sp falls because I can buy cheap and when it rises. There is nothing you can do about magic pill craze, time to short $LLY which is way behind. Earnings will be very interesting! Novo back to all time highs 💊 🚀
0 · Reply
Fibonacci5
Fibonacci5 Jan. 23 at 10:03 PM
$LLY potential diamond top ?
0 · Reply
TechTraderGrok
TechTraderGrok Jan. 23 at 9:41 PM
Covered $LLY at $1065.44 (-3.2%). From Grok: "Ventyx $1.2B acquisition rallies LLY calming Wegovy pill concerns despite orforglipron delay—cover short to lock gains." https://www.techtrader.ai/grokwall/?post=16206&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
BioRich
BioRich Jan. 23 at 8:57 PM
$ALT Not a cross post, but if you're hear thinking about big news or buyouts, swing over to $GUTS. They will have massive data release within the next week (possibly after hours) that will catapult them to a multiple as soon as data is released (obviously pending excellent results, which is expected). They are the leader in weight loss retention following GLP-1 discontinuation. You may have seen $LLY just released data that was good for weight loss retention; $GUTS provides a one time procedure that keeps the weight off. Insane potential and growth expected GIA, massive M&A target. Worth a look. Again, don't take my word for it, but if you're looking for the "next big thing", $ALT is not it...I believe $GUTS is. Follow/Subscribe for more suggestions and perspective from our growing community. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
2 · Reply
Dill27
Dill27 Jan. 23 at 8:27 PM
$NVO If $LLY where to share record breaking data, it would be up 20%.
0 · Reply
StocktwitsNews
StocktwitsNews Jan. 23 at 8:19 PM
Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week $NVO $LLY $DFAX https://stocktwits.com/news/equity/markets/novo-nordisk-in-green-after-oral-wegovy-clocks-over-18k-prescriptions-in-week/cmyRi8gR4Wb
0 · Reply
Punit
Punit Jan. 23 at 8:09 PM
$SPY $LLY $PFE $MRNA THE CHAIR OF THE FEDERAL PANEL THAT RECOMMENDS VACCINES FOR AMERICANS SAID THAT SHOTS AGAINST POLIO AND MEASLES — AND PERHAPS ALL DISEASES — SHOULD BE OPTIONAL
1 · Reply
clan
clan Jan. 23 at 7:55 PM
$MNKD Funny how the {Proboards} "boo-birds", use median income in India as a foolish/false rationale to support a negative prognostication toward a failure of Afrezza. What a bunch of maroons. Cipla only needs to capture 1/2 of 1% of the wealthiest diabetic Indians to create a boon for Mannkind, and its shareholders. 🚫💉🇮🇳 $LLY $NVO
0 · Reply
AaronSpencer
AaronSpencer Jan. 23 at 7:19 PM
$MLTX Regardless of the potential $LLY and $MRK buyout rumours, $MLTX has a gap that needs to be filled ($32-$35).
2 · Reply
JLInvest
JLInvest Jan. 23 at 7:16 PM
$NVO It only gets better with a weaker dollar. I have a 4% yield on this stock. Which is higher with the currency kicker. Add in this is trading 18x forward while $LLY is now at 32x. One is taking market share and one is losing it. Do the math This ride isnt over yet.
1 · Reply
Flabslab
Flabslab Jan. 23 at 6:06 PM
$LLY Why the drop?
0 · Reply
TopWaterSniper
TopWaterSniper Jan. 23 at 5:01 PM
$NVO $LLY what no one is talking about is how many of those 18k+ new scripts replaced an Ozempic shot script. Of course Novo will lose shot patients as well but they will be conversions. Will Lilly have to warn on guidance if the scripts keep ripping before their pill hits? 🤔
1 · Reply
RSpades
RSpades Jan. 23 at 4:34 PM
$LLY Season starts in April.
0 · Reply
Tokenist
Tokenist Jan. 23 at 4:10 PM
🍽️💊 $NVO catching a bid today — and it’s not hype, it’s scripts. Novo’s new oral Wegovy pill just logged 18,000+ prescriptions in week ONE 😮‍💨 (and that doesn’t even count online orders via NovoCare). For context: $LLY’s Zepbound hit ~8,000 in its second week. Even better for bulls: the pill launch isn’t stealing from injectable Wegovy, injectables actually added ~2,000 scripts WoW, meaning this looks like market expansion, not cannibalization. Goldman just slapped a Buy on $NVO too, saying the pill momentum could juice near-term earnings. Next big checkpoint: Feb 4 earnings - guidance + rollout speed could decide if this move keeps running… or fades like a sugar high. 🔥📈
1 · Reply
GreenEnergy2022
GreenEnergy2022 Jan. 23 at 3:58 PM
$ALT The science never lie. Best in class "These are industry leading results, compared to a cT1 reduction of 110ms with 15mg tirzepatide at 52 weeks. A cT1 reduction of 88ms is clinically significant for MASH resolution." $LLY $NVO $MDGL
0 · Reply
ZacksResearch
ZacksResearch Jan. 23 at 3:44 PM
$LLY's oncology growth shines amidst GLP-1 momentum! Oncology sales hit $6.77B in 9 months, up about 9% in the same period, making up 15% of total revenue. Verzenio & new breast cancer drug Inluriyo launch are crucial developments. Stock up 35% in 6 months despite high valuation with a forward P/E of 32.02. Is LLY's growth sustainable beyond its obesity segment? Full analysis here 👉 https://www.zacks.com/stock/news/2821783/heres-how-eli-lillys-oncology-drugs-are-poised-ahead-of-q4-earnings?cid=sm-stocktwits-2-2821783-body-30218&ADID=SYND_STOCKTWITS_TWEET_2_2821783_BODY_30218
0 · Reply
usiv
usiv Jan. 23 at 3:21 PM
$LLY need to clear 1100-1108 zone
0 · Reply
TeaMartinez4
TeaMartinez4 Jan. 23 at 3:17 PM
$LLY well that’s frustrating, right back to old resistance. lol
0 · Reply
DefenseMania
DefenseMania Jan. 23 at 2:50 PM
$GILD true value $175.00 in 2026 If it doesn’t get acquired first :) $AZN $PFE $LLY
0 · Reply
Princeb
Princeb Jan. 23 at 2:47 PM
$ALT while I'm delighted over the run the post few days, wake me when we hit 13$ from two years ago. Then wake me again when we hit 40$ on buy out. Novo needs to have a MASH liver fibrosis reversing drug $LLY $NVO
0 · Reply